跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 10,880 条关于
“unresectable HCC”
全部
10,880
临床试验
9,439
药物
297
机构
21
资讯
1,123
去年
TACE Plus Camrelizumab and Rivoceranib Improves PFS in Unresectable HCC
去年
Expert Outlines Patient-Specific Approach for IO Combinations in Unresectable HCC Treatment
去年
FDA Accepts NDA Resubmission for Rivoceranib/Camrelizumab Combo in Unresectable HCC
3年前
FDA Accepts NDA for Rivoceranib and Camrelizumab Combination in Unresectable Hepatocellular Carcinoma
去年
ABK Biomedical's Eye90 Microspheres Receives FDA Clearance to Advance Route90 Trial for Unresectable HCC
2年前
Elevar Therapeutics Plans NDA Resubmission for Rivoceranib/Camrelizumab in Unresectable HCC After CRL
去年
Tecentriq and Avastin Combined with TACE Shows Significant Benefit in Unresectable Liver Cancer Trial
去年
Combination Therapies Reshape Frontline HCC Treatment Landscape
2年前
Camrelizumab Plus Rivoceranib Shows Sustained Survival Benefit in Unresectable HCC
去年
Advances and Challenges in Hepatocellular Carcinoma (HCC) Treatment Highlighted in Recent Studies
第 1 页,共 113 页
上一页
下一页